ES2112929T3 - Derivados de acido hidroxamico y composiciones farmaceuticas de ellos. - Google Patents

Derivados de acido hidroxamico y composiciones farmaceuticas de ellos.

Info

Publication number
ES2112929T3
ES2112929T3 ES93109443T ES93109443T ES2112929T3 ES 2112929 T3 ES2112929 T3 ES 2112929T3 ES 93109443 T ES93109443 T ES 93109443T ES 93109443 T ES93109443 T ES 93109443T ES 2112929 T3 ES2112929 T3 ES 2112929T3
Authority
ES
Spain
Prior art keywords
alkyl
atom
amino acid
carbamoyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93109443T
Other languages
English (en)
Inventor
Michael John Broadhurst
Paul Anthony Brown
William Henry Johnson
Geoffrey Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929213473A external-priority patent/GB9213473D0/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2112929T3 publication Critical patent/ES2112929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Abstract

LA INVENCION SUMINISTRA DERIVADOS DE ACIDO HIDROXAMICO DE LA FORMULA I EN LA QUE R1 REPRESENTA ALQUIL C1-C7; R2 REPRESENTA HIDROGENO, ALQUIL C1-C6 O UN GRUPO DE LA FORMULA -(CH2)N-ARIL O -(CH2)N-HET EN LAS CUALES N VALE ENTRE 1 Y 4 Y HET REPRESENTA UN ANILLO N-HETEROCICLICO DE 5 O 6 MIEMBROS QUE (A) ESTA UNIDO POR MEDIO DEL ATOMO DE N; (B) CONTIENE OPCIONALMENTE N, O Y/O S COMO ATOMOS HETEROS ADICIONALES EN UNA POSICION O POSICIONES DIFERENTES DE LAS ADYACENTES AL ENLACE DEL ATOMO N, (C) ESTA SUSTITUIDO POR OXO EN UNO O AMBOS ATOMOS DE C ADYACENTES AL ENLACE DE ATOMO DE N Y (D) ESTA OPCIONALMENTE SUSTITUIDO EN UNO O MAS ATOMOS DE CARBONO POR ALQUIL C1-C6 U OXO Y/O EN CUALQUIER ATOMO DE N ADICIONAL POR ALQUIL C1-C6; R3 REPRESENTA EL GRUPO CARACTERIZADOR DE UN ACIDO DE (ALFA)-AMINO NATURAL O NO NATURAL EN EL QUE CUALQUIER GRUPO FUNCIONAL PRESENTE PUEDE ESTAR PROTEGIDO CON LA CONDICION DE QUE R3 NO REPRESENTE HIDROGENO; R4 REPRESENTA CARBOXIL (ALCOXIDO C1-C6)-CARBONIL, CARBAMOIL O (ALQUIL C1C6)-CARBAMOIL; R5 REPRESENTA EL GRUPO CARACTERIZADOR DE UN ACIDO DE (ALFA)-AMINO QUE SE PRODUCE DE FORMA NATURAL EN EL CUAL CUALQUIER GRUPO FUNCIONAL PUEDE ESTAR PROTEGIDO; Y R6 REPRESENTA HIDROGENO; O R4, R5 Y R6 REPRESENTAN CADA UNA INDIVIDUALMENTE ALQUIL C1-C6, ASIMISMO SE PRESENTAN LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS COMPUESTOS, QUE SON INHIBIDORES DE LA METALOPROTEINASA DE MATRIZ UTIL PARA EL CONTROL O PREVENCION DE ENFERMEDADES ARTICULARES DEGENERATIVAS TALES COMO LA ARTRITIS REUMATOIDE Y LA OSTEOARTRITIS O PARA EL TRATAMIENTO DE TUMORES INVASIVOS, ARTERIOSCLEROSIS O ESCLEROSIS MULTIPLE. LOS COMPUESTOS PUEDEN MANUFACTURARSE DE ACUERDO CON METODOS YA CONOCIDOS DESPROTEGIENDO UN CORRESPONDIENTE NUEVO COMPUESTO DE BENCILOXIAMINO O MEDIANTE HIDROXAMIDACION DE UN CORRESPONDIENTE NUEVO AMINOACIDO O DERIVADO ACTIVADO DEL MISMO.
ES93109443T 1992-06-25 1993-06-14 Derivados de acido hidroxamico y composiciones farmaceuticas de ellos. Expired - Lifetime ES2112929T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213473A GB9213473D0 (en) 1992-06-25 1992-06-25 Hydroxamic acid derivatives
GB939307081A GB9307081D0 (en) 1992-06-25 1993-04-05 Hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
ES2112929T3 true ES2112929T3 (es) 1998-04-16

Family

ID=26301123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93109443T Expired - Lifetime ES2112929T3 (es) 1992-06-25 1993-06-14 Derivados de acido hidroxamico y composiciones farmaceuticas de ellos.

Country Status (19)

Country Link
EP (1) EP0575844B1 (es)
JP (1) JP2594014B2 (es)
CN (1) CN1054599C (es)
AT (1) ATE162514T1 (es)
AU (1) AU666727B2 (es)
BG (1) BG97895A (es)
CA (1) CA2098166A1 (es)
CZ (1) CZ118393A3 (es)
DE (1) DE69316456T2 (es)
DK (1) DK0575844T3 (es)
ES (1) ES2112929T3 (es)
FI (1) FI932950A (es)
GR (1) GR3026623T3 (es)
HU (1) HU9301773D0 (es)
IL (1) IL106059A0 (es)
IS (1) IS4041A (es)
NO (1) NO932326L (es)
NZ (1) NZ247926A (es)
SK (1) SK64993A3 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제
GB2315750B (en) * 1994-01-22 1998-07-01 British Biotech Pharm Metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
EP0832875B1 (en) 1995-04-25 2004-06-30 Daiichi Fine Chemical Co., Ltd. Highly water-soluble metalloproteinase inhibitor
WO1996033733A1 (fr) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Nouveau remede pour affections cutanees
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
ATE272062T1 (de) * 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
KR20000035925A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
CN1228772A (zh) 1996-08-28 1999-09-15 普罗克特和甘保尔公司 杂环金属蛋白酶抑制剂
CA2264045A1 (en) * 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
PL191366B1 (pl) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Zastosowanie pochodnych kwasu hydroksamowego, pochodne kwasu hydroksamowego oraz kompozycje farmaceutyczne je zawierające
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
KR20020081465A (ko) 2000-03-21 2002-10-26 더 프록터 앤드 갬블 캄파니 헤테로시클릭 측쇄 함유, ｎ-치환된 메탈로프로테아제저해제
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
DE69108529T2 (de) * 1990-12-03 1995-11-30 Celltech Therapeutics Ltd Peptidylderivate.

Also Published As

Publication number Publication date
SK64993A3 (en) 1994-01-12
AU3993193A (en) 1994-01-06
DK0575844T3 (da) 1998-09-14
CA2098166A1 (en) 1993-12-26
FI932950A (fi) 1993-12-26
FI932950A0 (fi) 1993-06-24
CZ118393A3 (en) 1994-02-16
EP0575844B1 (en) 1998-01-21
JPH0687813A (ja) 1994-03-29
DE69316456T2 (de) 1998-07-09
IS4041A (is) 1993-12-26
EP0575844A2 (en) 1993-12-29
CN1082027A (zh) 1994-02-16
NO932326L (no) 1993-12-27
AU666727B2 (en) 1996-02-22
BG97895A (en) 1994-06-30
HU9301773D0 (en) 1993-09-28
NO932326D0 (no) 1993-06-24
DE69316456D1 (de) 1998-02-26
JP2594014B2 (ja) 1997-03-26
NZ247926A (en) 1995-10-26
ATE162514T1 (de) 1998-02-15
IL106059A0 (en) 1993-10-20
CN1054599C (zh) 2000-07-19
GR3026623T3 (en) 1998-07-31
EP0575844A3 (es) 1994-03-09

Similar Documents

Publication Publication Date Title
ES2112929T3 (es) Derivados de acido hidroxamico y composiciones farmaceuticas de ellos.
IL113419A0 (en) Hydroxamic acid derivatives their preparation and pharmaceutical compositions containing them
MY108798A (en) Hydroxamic acid derivatives.
DE69200766T2 (de) Phenylamidinderivate als plättchenaggregationsinhibitoren.
MY117290A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
DE69413237D1 (en) Plättchenaggregationsinhibitoren
MY134743A (en) Derivatives of hydroxyamino-succinic acid

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 575844

Country of ref document: ES